 |
14 Diseases |  |
33 Trials |
|
33 Trials |  |
2608 News |  |
| «12...20212223242526272829303132» |
- |||| teriflunomide / Generic mfg.
Phase classification, Trial completion date, Trial primary completion date: An Observational Study on Teriflunomide-exposed Pregnancies (clinicaltrials.gov) - Apr 2, 2018
P, N=325, Recruiting, Sponsor: Sanofi
Phase classification: P=N/A --> P | Trial completion date: Jul 2019 --> Feb 2022 | Trial primary completion date: Jul 2019 --> Feb 2022
- | Trial completion date, Trial primary completion date: MIST: Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy (clinicaltrials.gov) - Mar 29, 2018
P2/3, N=5, Recruiting, Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
Phase classification: P=N/A --> P | Trial completion date: Jul 2019 --> Feb 2022 | Trial primary completion date: Jul 2019 --> Feb 2022 Trial completion date: Nov 2017 --> Dec 2021 | Trial primary completion date: Nov 2017 --> Dec 2021
- | Tysabri (natalizumab) / Biogen, Royalty
Trial primary completion date: MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV (clinicaltrials.gov) - Mar 22, 2018
P4, N=70, Active, not recruiting, Sponsor: Multiple Sclerosis Center of Northeastern New York
Trial completion date: Nov 2017 --> Dec 2021 | Trial primary completion date: Nov 2017 --> Dec 2021 Trial primary completion date: Dec 2017 --> Jun 2018
- || Tysabri (natalizumab) / Biogen, Royalty
Enrollment closed: Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries (clinicaltrials.gov) - Mar 22, 2018
P=N/A, N=34600, Active, not recruiting, Sponsor: Biogen
Trial primary completion date: Dec 2017 --> Jun 2018 Not yet recruiting --> Active, not recruiting
- | teriflunomide / Generic mfg.
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: TERICIS: A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period (clinicaltrials.gov) - Mar 20, 2018
P3, N=5, Active, not recruiting, Sponsor: Centre Hospitalier Universitaire de Nice
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting | N=11 --> 5 | Trial completion date: Oct 2018 --> Jan 2019 | Trial primary completion date: Oct 2018 --> Jan 2019
- | teriflunomide / Generic mfg.
New trial: Mechanistic Studies of Teriflunomide in RRMS (clinicaltrials.gov) - Mar 13, 2018
P=N/A, N=30, Not yet recruiting, Sponsor: University of Michigan
- | teriflunomide / Generic mfg.
New P4 trial: nd nd (EUDRACT) - Mar 8, 2018
P4, N=30, Ongoing, Sponsor: UNIVERSIT
- ||| Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Trial completion date: ASCLEPIOS I: Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis (clinicaltrials.gov) - Mar 3, 2018
P3, N=900, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Active, not recruiting | N=11 --> 5 | Trial completion date: Oct 2018 --> Jan 2019 | Trial primary completion date: Oct 2018 --> Jan 2019 Trial completion date: Jul 2019 --> May 2019
- ||| teriflunomide / Generic mfg.
Trial completion date: TERIKIDS: Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Mar 3, 2018
P3, N=166, Active, not recruiting, Sponsor: Genzyme, a Sanofi Company
Trial completion date: Jul 2019 --> May 2019 Trial completion date: Oct 2021 --> Sep 2021
- | teriflunomide / Generic mfg.
Enrollment open: TERIPET: Effect of Teriflunomide Treatment on Microglial Activation in an MS Patient Cohort at Risk of Progression (clinicaltrials.gov) - Feb 8, 2018
P=N/A, N=30, Recruiting, Sponsor: Turku University Hospital
Trial completion date: Oct 2021 --> Sep 2021 Not yet recruiting --> Recruiting
- ||||| teriflunomide / Generic mfg.
Enrollment closed: TERIKIDS: Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Feb 5, 2018
P3, N=166, Active, not recruiting, Sponsor: Genzyme, a Sanofi Company
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Tysabri (natalizumab) / Biogen, Royalty
New trial: Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries (clinicaltrials.gov) - Jan 17, 2018
P=N/A, N=34600, Not yet recruiting, Sponsor: Biogen
- |||||| teriflunomide / Generic mfg.
Enrollment open: TERIS: Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome (clinicaltrials.gov) - Nov 30, 2017
P3, N=200, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nice
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| teriflunomide / Generic mfg.
New trial: PREMISEP: Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration (clinicaltrials.gov) - Oct 13, 2017
P=N/A, N=650, Recruiting, Sponsor: University Hospital, Caen
- teriflunomide / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis. (clinicaltrials.gov) - Sep 15, 2017
P=N/A, N=26, Terminated, Sponsor: University of North Carolina, Chapel Hill
Not yet recruiting --> Recruiting N=46 --> 26 | Recruiting --> Terminated | Trial primary completion date: May 2017 --> Dec 2016
- |||||||||| Briumvi (ublituximab-xiiy) / TG Therap, Neuraxpharm
New P3 trial: ULTIMATE 2: Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) (clinicaltrials.gov) - Sep 11, 2017
P3, N=440, Recruiting, Sponsor: TG Therapeutics, Inc.
- |||||||||| Briumvi (ublituximab-xiiy) / TG Therap, Neuraxpharm
New P3 trial: Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) (clinicaltrials.gov) - Sep 11, 2017
P3, N=440, Recruiting, Sponsor: TG Therapeutics, Inc.
- |||| teriflunomide / Generic mfg.
Trial primary completion date: TERIKIDS: Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Sep 8, 2017
P3, N=165, Recruiting, Sponsor: Genzyme, a Sanofi Company
N=46 --> 26 | Recruiting --> Terminated | Trial primary completion date: May 2017 --> Dec 2016 Trial primary completion date: Oct 2017 --> Dec 2019
- | Tysabri (natalizumab) / Biogen, Royalty
Trial primary completion date: MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV (clinicaltrials.gov) - Aug 29, 2017
P4, N=70, Active, not recruiting, Sponsor: Multiple Sclerosis Center of Northeastern New York
Trial primary completion date: Oct 2017 --> Dec 2019 Trial primary completion date: Mar 2017 --> Dec 2017
- ||||| Arzerra (ofatumumab) / Novartis, Genmab
Trial initiation date: ASCLEPIOS II: Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. (clinicaltrials.gov) - Aug 21, 2017
P3, N=900, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Mar 2017 --> Dec 2017 Initiation date: Jan 2016 --> Aug 2016
- ||||| Arzerra (ofatumumab) / Novartis, Genmab
Trial initiation date: ASCLEPIOS II: Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. (clinicaltrials.gov) - Jul 16, 2017
P3, N=900, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Jan 2016 --> Aug 2016 Initiation date: Aug 2016 --> Jan 2016
- ||| teriflunomide / Generic mfg.
New trial: An Observational Study on Teriflunomide-exposed Pregnancies (clinicaltrials.gov) - Jun 26, 2017
P=N/A, N=325, Recruiting, Sponsor: Sanofi
- || teriflunomide / Generic mfg.
Phase classification, Trial initiation date, Trial primary completion date: Teriflunomide Observational Effectiveness Study (clinicaltrials.gov) - May 24, 2017
P=N/A, N=300, Enrolling by invitation, Sponsor: Centre hospitalier de l'Universit
Initiation date: Aug 2016 --> Jan 2016 Phase classification: P4 --> P=N/A | Initiation date: Jul 2015 --> Nov 2015 | Trial primary completion date: Jul 2017 --> Dec 2018
- | teriflunomide / Generic mfg., cyclophosphamide / Generic mfg.
Enrollment closed: Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study (clinicaltrials.gov) - May 22, 2017
P3, N=110, Active, not recruiting, Sponsor: Northwestern University
Phase classification: P4 --> P=N/A | Initiation date: Jul 2015 --> Nov 2015 | Trial primary completion date: Jul 2017 --> Dec 2018 Recruiting --> Active, not recruiting
- | teriflunomide / Generic mfg.
Trial primary completion date: Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis (clinicaltrials.gov) - Apr 25, 2017
P=N/A, N=60, Recruiting, Sponsor: State University of New York at Buffalo
Recruiting --> Active, not recruiting Trial primary completion date: Feb 2017 --> Aug 2018
- |||||||||| teriflunomide / Generic mfg.
New P3 trial: TERIS: Randomized, Double-blinded Study of Treatment:Teriflunomide, in Radiologically Isolated Syndrome (clinicaltrials.gov) - Apr 20, 2017
P3, N=200, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de Nice
- ||||| Ponvory (ponesimod) / Juvise Pharma, Vanda
Enrollment closed, Head-to-Head: OPTIMUM: Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis (clinicaltrials.gov) - Mar 31, 2017
P3, N=1100, Active, not recruiting, Sponsor: Actelion
Trial primary completion date: Feb 2017 --> Aug 2018 Recruiting --> Active, not recruiting
- ||| Trial completion, Trial primary completion date, Real-world evidence, Real-world: EFFECT: Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Mar 23, 2017
P=N/A, N=2978, Completed, Sponsor: Biogen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Dec 2016
- | teriflunomide / Generic mfg.
Trial primary completion date: Teriflunomide Male Transmission Study (clinicaltrials.gov) - Feb 27, 2017
P=N/A, N=40, Recruiting, Sponsor: Griffin Hospital
Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Dec 2016 Trial primary completion date: Oct 2016 --> Oct 2017
- || Enrollment closed, Real-world evidence, Real-world: EFFECT: Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Jan 13, 2017
P=N/A, N=2978, Active, not recruiting, Sponsor: Biogen
Trial primary completion date: Oct 2016 --> Oct 2017 Recruiting --> Active, not recruiting
- |||| teriflunomide / Generic mfg.
Trial primary completion date: TERIKIDS: Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Nov 30, 2016
P3, N=165, Recruiting, Sponsor: Genzyme, a Sanofi Company
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2021 --> Oct 2017
- |||||| Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Enrollment open: ASCLEPIOS I: Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis (clinicaltrials.gov) - Nov 14, 2016
P3, N=900, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Aug 2021 --> Oct 2017 Not yet recruiting --> Recruiting
- Tysabri (natalizumab) / Biogen, Royalty
Enrollment closed, Trial primary completion date: MAIN STUDY: SWITCH SUB-STUDY: SWITCH-JCV (clinicaltrials.gov) - Oct 26, 2016
P4, N=70, Active, not recruiting, Sponsor: Multiple Sclerosis Center of Northeastern New York
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Mar 2017
- |||||| Arzerra (ofatumumab) / Novartis, Genmab
Enrollment open: ASCLEPIOS II: Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. (clinicaltrials.gov) - Sep 19, 2016
P3, N=900, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Mar 2017 Not yet recruiting --> Recruiting
- teriflunomide / Generic mfg., colestipol / Generic mfg.
Enrollment change, Trial termination: TERCOL: Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride (clinicaltrials.gov) - Sep 16, 2016
P1, N=14, Terminated, Sponsor: Derrick Scott Robertson
N=30 --> 14 | Recruiting --> Terminated; PK time points were not being met as expected. Determination that risks outweighed benefit.
- ||| Enrollment open, Real-world evidence, Real-world: EFFECT: Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - Aug 3, 2016
P=N/A, N=3000, Recruiting, Sponsor: Biogen
Determination that risks outweighed benefit. Not yet recruiting --> Recruiting
- teriflunomide / Generic mfg.
New trial: Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis. (clinicaltrials.gov) - Jul 14, 2016
P=N/A, N=46, Recruiting, Sponsor: University of North Carolina, Chapel Hill
- |||||||||| Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
New P3 trial: ASCLEPIOS I: Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis (clinicaltrials.gov) - Jun 9, 2016
P3, N=900, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- |||||||||| Arzerra (ofatumumab) / Novartis, Genmab
New P3 trial: ASCLEPIOS II: Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. (clinicaltrials.gov) - Jun 9, 2016
P3, N=900, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||| New trial, Real-world evidence, Real-world: EFFECT: Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) (clinicaltrials.gov) - May 18, 2016
P=N/A, N=3000, Not yet recruiting, Sponsor: Biogen
- |||| Ponvory (ponesimod) / Juvise Pharma, Vanda
Trial primary completion date, Head-to-Head: OPTIMUM: Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis (clinicaltrials.gov) - May 2, 2016
P3, N=1100, Recruiting, Sponsor: Actelion
Not yet recruiting --> Recruiting Trial primary completion date: Apr 2018 --> Dec 2018
- ||||||| teriflunomide / Generic mfg.
Trial completion: TOPIC: Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis (clinicaltrials.gov) - Mar 24, 2016
P3, N=618, Completed, Sponsor: Sanofi
Trial primary completion date: Apr 2018 --> Dec 2018 Active, not recruiting --> Completed
- teriflunomide / Generic mfg., cyclophosphamide / Generic mfg.
Trial primary completion date: Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study (clinicaltrials.gov) - Mar 22, 2016
P3, N=110, Recruiting, Sponsor: Northwestern University
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Dec 2017
- teriflunomide / Generic mfg., colestipol / Generic mfg.
Trial primary completion date: TERCOL: Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride (clinicaltrials.gov) - Mar 18, 2016
P1, N=30, Recruiting, Sponsor: Derrick Scott Robertson
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2015 --> Jun 2016
- teriflunomide / Generic mfg.
Trial completion, Trial primary completion date: Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months (clinicaltrials.gov) - Feb 12, 2016
P=N/A, N=50, Completed, Sponsor: University at Buffalo
Trial primary completion date: Dec 2015 --> Jun 2016 Recruiting --> Completed | Trial primary completion date: Nov 2014 --> Oct 2015
- teriflunomide / Generic mfg.
New trial: Teriflunomide Male Transmission Study (clinicaltrials.gov) - Feb 10, 2016
P=N/A, N=40, Recruiting, Sponsor: Griffin Hospital
- ||||||| teriflunomide / Generic mfg.
Trial completion, Enrollment change: Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Jan 27, 2016
P3, N=742, Completed, Sponsor: Sanofi
Recruiting --> Completed | Trial primary completion date: Nov 2014 --> Oct 2015 Active, not recruiting --> Completed | N=1080 --> 742
- |||| teriflunomide / Generic mfg.
Enrollment open: Teriflunomide Observational Effectiveness Study (clinicaltrials.gov) - Jan 26, 2016
P4, N=300, Enrolling by invitation, Sponsor: Centre hospitalier de l'Universit
Active, not recruiting --> Completed | N=1080 --> 742 Not yet recruiting --> Enrolling by invitation
- teriflunomide / Generic mfg.
New trial: Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis (clinicaltrials.gov) - Jan 11, 2016
P=N/A, N=60, Recruiting, Sponsor: State University of New York at Buffalo
- |||| teriflunomide / Generic mfg.
Trial primary completion date: TERIKIDS: Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis (clinicaltrials.gov) - Dec 14, 2015
P3, N=165, Recruiting, Sponsor: Genzyme, a Sanofi Company
Not yet recruiting --> Enrolling by invitation Trial primary completion date: Jan 2020 --> Aug 2021